Actively Recruiting
Prospective Validation of the OHI Index
Led by Meir Medical Center · Updated on 2025-05-13
300
Participants Needed
2
Research Sites
469 weeks
Total Duration
On this page
Sponsors
M
Meir Medical Center
Lead Sponsor
C
Children's Hospital Medical Center, Cincinnati
Collaborating Sponsor
AI-Summary
What this Trial Is About
Hemophagocytic lymphohistiocytosis (HLH) associated with hematologic malignancies (HM-HLH) is a syndrome with an abysmal prognosis (10-30% 5 years overall survival). The investigators have recently established an improved diagnostic and prognostic index for HM-HLH, termed the Optimized HLH Inflammatory (OHI) index. The OHI index is comprised of the combined elevation of soluble CD25 (sCD25) \> 3,900 U/mL and ferritin \>1,000 ng/mL . However, the true incidence and outcomes of HLH/OHI+ in an unselected cohort are unknown, and so is the mechanism of HM-HLH.
CONDITIONS
Official Title
Prospective Validation of the OHI Index
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with hematologic malignancies
- At least 18 years old
You will not qualify if you...
- Prior recent treatment with chemotherapy or other cytoreductive therapies in the last month
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Meir Medical Center
Kfar Saba, Israel, 4428164
Actively Recruiting
2
Rabin Medical Center
Petah Tikva, Israel, 49100
Actively Recruiting
Research Team
A
Adi Zoref Lorenz, MD
CONTACT
N
Noa Rabinowicz, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here